molecules of the month

Vixotrigine (BIIB074)

BP, use-dependent sodium channel blocker

Ph. II oral efficacy in trigeminal neuralgia

from cell-based HTS and ligand-based opt.

ACS Med. Chem. Lett., Jul. 16, 2020

biogen / Convergence / GSK, MA / UK

Structure of Vixotrigine (BIIB074), a voltage- and use-dependent sodium channel blocker
1 min read

Vixotrigine (BIIB074) is a voltage-gated sodium channel blocker that preferentially binds to the inactivated state of the sodium channels, conferring selectivity for channels involved in pain-associated high frequency nerve signalling over normal low frequency nerve signalling (use-/state-dependence). The use-dependent activity is believed to confer a better safety window over previous generations of sodium channel inhibitors. Two Ph. III clinical trials appear to be planned for trigeminal neuralgia with estimated start dates in mid-2021.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: